Абстракт

Objectives: The objective of this study is to introduce a novel 589-nm Raman-based solid-state vascular laser and to demonstrate its optical principles, technical advantages, and clinical potential as an alternative to pulsed dye lasers. Participants will gain an understanding of how solid-state Raman technology improves wavelength stability, reduces maintenance burden, and enables effective, patient-friendly treatment of cutaneous vascular lesions. Introduction: Cutaneous vascular lesions such as hemangiomas, port-wine stains, and telangiectasia are commonly treated with pulsed dye lasers (PDL). Despite proven efficacy, PDL systems rely on consumable dye, require frequent calibration, and incur high maintenance costs, with potential output instability over time. To address these limitations, a novel 589nm Potassium Gadolinium Tungstate (KGW) Raman Laser was developed to deliver stable oxyhemoglobin-targeted energy with improved practicality. Materials / method: A 589nm KGW Raman laser architecture that generates a Stokes-shifted 589-nm wavelength optimized for vascular targeting. The use of a solid Raman crystal eliminates dye degradation and replacement. The system allows adjustable spot sizes, pulse durations, fluence, and repetition rates, with integrated dynamic cooling. Pre-clinical testing was performed on cutaneous vascular lesions using mathematically derived parameters to evaluate beam stability, safety, and therapeutic response. Results: The system demonstrated stable 589-nm output with energy stability within 5% and a uniform flat-top beam profile across spot sizes ranging from 5×5 to 12×12 mm². Energy delivery reached up to 10 J with repetition rates of 1–10 Hz. Pulse durations were adjustable from 0.5–40 ms, including burst modes mimicking PDL pulse structures. Dynamic cooling enhanced patient safety. Pre-clinical evaluations showed effective vascular responses without significant adverse effects. Conclusion: The 589nm KGW Raman laser represents a promising alternative to conventional pulsed dye lasers by providing stable wavelength output, reduced maintenance requirements, and effective vascular targeting. Early results demonstrate favorable safety and efficacy profiles, suggesting this technology may expand treatment options and improve clinical efficiency in vascular dermatology. Larger controlled clinical studies are ongoing prior to planned commercialization in early 2026.